IHAM
Integral Health Asset Management Portfolio holdings
AUM
$1.07B
This Quarter Return
+8.51%
1 Year Return
+40.53%
3 Year Return
+328.04%
5 Year Return
+535.34%
10 Year Return
–
AUM
$1.13B
AUM Growth
+$1.13B
(+33%)
Cap. Flow
+$321M
Cap. Flow
% of AUM
28.43%
Top 10 Holdings %
Top 10 Hldgs %
39.2%
Holding
99
New
35
Increased
28
Reduced
13
Closed
17
Top Buys
| 1 |
Centene
CNC
|
$30.3M |
| 2 |
Cardinal Health
CAH
|
$29.6M |
| 3 |
Vera Therapeutics
VERA
|
$27.5M |
| 4 |
CVS Health
CVS
|
$22.4M |
| 5 |
Neurocrine Biosciences
NBIX
|
$21.8M |
Top Sells
| 1 |
LBPH
Longboard Pharmaceuticals, Inc. Common Stock
LBPH
|
$35M |
| 2 |
Novartis
NVS
|
$23M |
| 3 |
Tenet Healthcare
THC
|
$16.4M |
| 4 |
Arcellx
ACLX
|
$13.4M |
| 5 |
Medtronic
MDT
|
$12M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
ATYR
76
aTyr Pharma
ATYR
$560M
| $1.36M | 0.12% |
+375,000
| New | +$1.36M |
|
77
Kyverna Therapeutics
KYTX
$161M
| $1.31M | 0.11% |
350,000
+150,000
| +75% | +$561K |
|
78
Alto Neuroscience
ANRO
$97.7M
| $1.27M | 0.11% |
+300,000
| New | +$1.27M |
|
79
Cabaletta Bio
CABA
$144M
| $1.14M | 0.1% |
500,000
+50,000
| +11% | +$114K |
|
80
Fate Therapeutics
FATE
$115M
| $990K | 0.08% |
600,000
-375,000
| -38% | -$619K |
|
|
CMPS
81
Compass Pathways
CMPS
$452M
| $756K | 0.06% |
+200,000
| New | +$756K |
|
|
LBPH
82
DELISTED
Longboard Pharmaceuticals, Inc. Common Stock
LBPH
| – | – |
-1,050,000
| Closed | -$35M |
|
83
Viridian Therapeutics
VRDN
$1.59B
| – | – |
-250,000
| Closed | -$5.69M |
|
84
Twist Bioscience
TWST
$1.57B
| – | – |
-100,000
| Closed | -$4.52M |
|
85
Tenaya Therapeutics
TNYA
$192M
| – | – |
-2,375,000
| Closed | -$4.58M |
|
86
Tango Therapeutics
TNGX
$745M
| – | – |
-200,000
| Closed | -$1.54M |
|
87
Tandem Diabetes Care
TNDM
$834M
| – | – |
-150,000
| Closed | -$6.36M |
|
88
Teleflex
TFX
$5.57B
| – | – |
-30,000
| Closed | -$7.42M |
|
89
Revvity
RVTY
$9.68B
| – | – |
-30,000
| Closed | -$3.83M |
|
|
90
Novartis
NVS
$248B
| – | – |
-200,000
| Closed | -$23M |
|
91
Intellia Therapeutics
NTLA
$1.26B
| – | – |
-100,000
| Closed | -$2.06M |
|
92
Neurogene
NGNE
$284M
| – | – |
-70,000
| Closed | -$2.94M |
|
93
Myriad Genetics
MYGN
$633M
| – | – |
-125,000
| Closed | -$3.42M |
|
94
IQVIA
IQV
$31.4B
| – | – |
-20,000
| Closed | -$4.74M |
|
95
GE HealthCare
GEHC
$33B
| – | – |
-20,000
| Closed | -$1.88M |
|
96
Evolent Health
EVH
$1.11B
| – | – |
-200,000
| Closed | -$5.66M |
|
97
Applied Therapeutics
APLT
$73.7M
| – | – |
-800,000
| Closed | -$6.8M |
|
98
Celldex Therapeutics
CLDX
$1.57B
| – | – |
0
| – | – |
|
99
CRISPR Therapeutics
CRSP
$4.82B
| – | – |
-150,000
| Closed | -$7.05M |
|